Skip to main content
. 2014 Apr 21;59(2):279–286. doi: 10.1093/cid/ciu270

Table 2.

Mortality Rates and Survival for 482 HIV-Infected Adults in the Center for AIDS Research Network of Integrated Clinical Systems Cohort With Lymphoma Between 1996 and 2011, Stratified by Histology and Unmasking Immune Reconstitution Inflammatory Syndrome Case Status

Case Status Persons Deaths Person-years Mortality Rate per 100 Person-years (95% CI) 6-mo Survival % (95% CI) 1-y Survival % (95% CI) 5-y Survival % (95% CI)
All lymphoma 482 229 1571 14.6 (12.8–16.6) 70 (66–75) 60 (55–65) 44 (40–50)
 IRIS 56 30 169 17.7 (12.4–23.4) 62 (50–76) 54 (42–69) 49 (37–64)
 Non-IRIS 426 199 1402 14.2 (12.4–16.3) 72 (67–77) 61 (56–67) 44 (39–50)
HL 80 25 302 8.3 (5.6–12.2) 82 (73–92) 77 (67–88) 61 (50–75)
 IRIS 12 2 52 3.9 (1.0–15.4) 82 (71–93) 83 (65–100) 83 (65–100)
 Non-IRIS 68 23 250 9.2 (6.1–13.8) 82 (73–93) 76 (65–89) 57 (45–73)
All NHL 402 204 1269 16.1 (14.0–18.4) 68 (63–73) 57 (51–62) 41 (36–47)
 IRIS 44 28 118 23.9 (16.5–34.6) 56 (43–73) 46 (34–64) 40 (27–58)
 Non-IRIS 358 176 1152 15.3 (13.2–17.7) 70 (64–76) 58 (53–65) 42 (36–48)
BL 57 23 157 14.6 (9.7–22.0) 73 (61–88) 63 (50–79) 51 (38–68)
 IRIS 5 3 5 62.7 (20.2–194.5) 60 (32–100) 40 (16–99) 40 (16–99)
 Non-IRIS 52 20 153 13.1 (8.5–20.3) 75 (62–90) 66 (53–82) 53 (39–71)
PCNSL 54 41 121 33.8 (24.9–45.9) 38 (27–54) 28 (18–43) 23 (14–37)
 IRIS 10 10 2 417.6 (224.7–776.2) 10 (2–4) 0 (0–0) 0 (0–0)
 Non-IRIS 44 31 119 26.1 (18.3–37.1) 45 (32–63) 34 (23–51) 28 (18–44)
DLBCL 205 101 692 14.6 (12.0–17.7) 75 (69–83) 64 (57–72) 44 (37–53)
 IRIS 22 10 85 11.8 (6.3–21.9) 72 (55–93) 67 (50–90) 54 (36–81)
 Non-IRIS 183 91 608 15.0 (12.2–18.4) 76 (69–84) 64 (56–72) 43 (36–52)
Other NHL 86 39 298 13.1 (9.6–17.9) 71 (60–84) 59 (47–73) 44 (33–59)
 IRIS 7 5 24 19.7 (8.2–47.4) 71 (46–100) 57 (32–100) 57 (32–100)
 Non-IRIS 79 34 273 12.5 (8.9–17.5) 71(59–86) 60 (47–75) 43 (32–58)

Abbreviations: BL, Burkitt lymphoma; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; HL, Hodgkin lymphoma; IRIS, immune reconstitution inflammatory syndrome; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma.